Neurocrine posts $1.1 billion quarter, raises INGREZZA sales guidanceNov 2Quarterly updateNeurocrine Biosciencesvalbenazine
Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readoutsJul 30Quarterly updateNeurocrine Biosciencesvalbenazine
Palvella Therapeutics adds Matthew Pauls to board of directorsJun 30PeoplePieris Pharmaceuticals, Inc.